---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-002126"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:06:53.350407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AbCellera FY2022 revenue $485M, net income $158.5M; 23 new partnered programs started

## Summary
- Total revenue $485.4M (up 29% YoY); net income $158.5M ($0.50 diluted EPS) vs $153.5M ($0.48 diluted) in 2021.
- Royalties from COVID antibodies bamlanivimab/bebtelovimab were $443M; EUA for bebtelovimab suspended in Q4.
- Partnership business: 23 new program starts, cumulative 101; 174 programs under contract with 40 partners.
- Q4 net loss $29.9M; cash and marketable securities $886.5M.

## SEC filing metadata
- accession: 0001564590-23-002126
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/0001564590-23-002126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/abcl-8k_20230221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-002126
- JSON: https://secwatch.observer/filing/0001564590-23-002126.json
- Plain text: https://secwatch.observer/filing/0001564590-23-002126.txt

## Key facts
- Earnings Releases
  AbCellera Biologics Inc. reported the year ended December 31, 2022 results: revenue $485.4 million in total revenue, net income $158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis, EPS $0.56 per share on a basic and $0.50 on a diluted basis.
  - Period: the year ended December 31, 2022
  - Revenue: $485.4 million in total revenue
  - Net income: $158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis
  - EPS: $0.56 per share on a basic and $0.50 on a diluted basis
  - Result: reported results
  source text: as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- abcl-ex991_43.htm Exhibit 99.1 NEWS RELEASE AbCellera Reports Full Year 2022 Business Results 02/21/2023 • Total revenue of $485 million, compared to $375 million in FY 2021 • Total cumulative partnered program starts of 101, with 23 new starts in the year • Net earnings of $0.56 per share on a basic and $0.50 on
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/0001564590-23-002126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.